Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Tony van Werkhooven who wrote (922)	6/26/1998 1:34:00 PM
From: NeuroInvestment	Read Replies (2) \| Respond to of 1491

Your assumption is quite correct. However, in appraising the benefits/costs of bringing in an allergy-targeting sales force, one can decide to see to what degree that market will be tapped otherwise, via advertising, etc....i.e. how much does one need the marketing partner, and at what price. I suspect the deal will ultimately be done, but only after some preliminary information regarding the 'osmosis' of Alrex into prescriber awareness is in. NeuroInvestment (www.neuroinv.com)